Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-75
SponsorBeijing Tiantan Hospital
About this trial
CLUE is a prospective study to assess structural and functional changes of the brain, spinal cord, and optic nerve, as well as the inflammatory environment in patients with neuroinflammatory and demyelinating diseases. Participants will receive magnetic resonance (MR) techniques including DIR, DKI, QSM, Rs-fMRI, conventional sequences (T1WI/T2WI/FLAIR), and the MR metabolic SPICE sequence, and will be followed up for one year using 3T MRI. In addition, participants will receive a one-time baseline examination including T1WI, T2WI, FLAIR, and SWI sequences on 7T MRI, as well as PET-MRI.
Eligibility criteria
Qualifiers
16-75
Diagnosis of neuroinflammatory and demyelination disease
Availability of demographic and clinical data at the time disease onset
Informed written consent obtained from the patient, and/or patient's parent(s), and/or legal representative. Assent, if old enough to grant, will be obtained from all patients under the age of 16 years.
Disqualifiers
Patients for whom MRI is contra-indicated
Patients included in an ongoing clinical trial where the product is blinded
Trial design
Treatments tested in this trial
- Intravenous steroid
Treatment groups
1,000 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov